Melalite XL Cream is a topical dermatological formulation combining Hydroquinone (2% w/w), Mometasone Furoate (0.1% w/w), and Tretinoin (0.025% w/w), designed for the management of hyperpigmentation disorders such as melasma, post-inflammatory hyperpigmentation, and other pigmentary abnormalities. Hydroquinone acts as a potent skin-lightening agent by inhibiting the enzyme tyrosinase, thereby reducing melanin synthesis. Mometasone Furoate, a medium-potency corticosteroid, provides anti-inflammatory and immunosuppressive effects, helping to reduce erythema, edema, and irritation associated with pigmentary conditions. Tretinoin, a retinoid derivative of vitamin A, promotes epidermal cell turnover and enhances penetration of hydroquinone, facilitating the removal of pigmented keratinocytes and improving skin texture. The synergistic combination in Melalite XL Cream offers effective depigmentation while minimizing inflammatory responses. It is indicated for short-term use under medical supervision due to potential side effects such as skin irritation, dryness, and steroid-related adverse effects including skin atrophy if used excessively. Patients should avoid excessive sun exposure and use sunscreen during treatment to prevent further pigmentation. Melalite XL Cream should be applied as directed by a healthcare professional, typically once daily at night, to achieve optimal therapeutic outcomes.